Moses Rodriguez

List of Publications by Year
in descending order

334 papers	23,412 citations	14655 66 h-index	10158 140 g-index
342 all docs	342 docs citations	342 times ranked	15841 citing authors

#	Article	IF	Citations
1	Association Between Time Spent Outdoors and Risk of Multiple Sclerosis. Neurology, 2022, 98, .	1.1	12
2	A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210914.	1.0	2
3	Nanogap dielectrophoresis combined with buffer exchange for detecting protein binding to trapped bioparticles. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2021, 611, 125829.	4.7	3
4	Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 857-876.	4.1	9
5	Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	4
6	Gut microbiome is associated with multiple sclerosis activity in children. Annals of Clinical and Translational Neurology, 2021, 8, 1867-1883.	3.7	21
7	Vitamin D genes influence MS relapses in children. Multiple Sclerosis Journal, 2020, 26, 894-901.	3.0	17
8	Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. Multiple Sclerosis Journal, 2020, 26, 1938-1947.	3.0	18
9	Remyelination-Promoting DNA Aptamer Conjugate Myaptavin-3064 Binds to Adult Oligodendrocytes In Vitro. Pharmaceuticals, 2020, 13, 403.	3.8	3
10	Pediatric Multiple Sclerosis Severity Score in a large US cohort. Neurology, 2020, 95, e1844-e1853.	1.1	11
11	Lipid-specific IgMs induce antiviral responses in the CNS: implications for progressive multifocal leukoencephalopathy in multiple sclerosis. Acta Neuropathologica Communications, 2020, 8, 135.	5.2	6
12	Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain, 2020, 143, 2733-2741.	7.6	45
13	Relapse recovery. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	13
14	Enhanced axonal response of mitochondria to demyelination offers neuroprotection: implications for multiple sclerosis. Acta Neuropathologica, 2020, 140, 143-167.	7.7	48
15	Antibody characterization using immunosignatures. PLoS ONE, 2020, 15, e0229080.	2.5	4
16	Realâ€World Effectiveness of Initial Diseaseâ€Modifying Therapies in Pediatric <scp>Multiple Sclerosis</scp>. Annals of Neurology, 2020, 88, 42-55.	5.3	68
17	Multiple Sclerosis: Melatonin, Orexin, and Ceramide Interact with Platelet Activation Coagulation Factors and Gut-Microbiome-Derived Butyrate in the Circadian Dysregulation of Mitochondria in Glia and Immune Cells. International Journal of Molecular Sciences, 2019, 20, 5500.	4.1	58
18	Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genetics, 2019, 15, e1007808.	3.5	48

#	Article	IF	Citations
19	mi RNA contributions to pediatricâ€onset multiple sclerosis inferred from GWAS. Annals of Clinical and Translational Neurology, 2019, 6, 1053-1061.	3.7	10
20	Glial cells as therapeutic targets in progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2019, 19, 481-494.	2.8	10
21	Optimization of a 40-mer Antimyelin DNA Aptamer Identifies a 20-mer with Enhanced Properties for Potential Multiple Sclerosis Therapy. Nucleic Acid Therapeutics, 2019, 29, 126-135.	3.6	10
22	Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis. Journal of Child Neurology, 2019, 34, 148-152.	1.4	5
23	Age is a critical determinant in recovery from multiple sclerosis relapses. Multiple Sclerosis Journal, 2019, 25, 1754-1763.	3.0	33
24	IgM Natural Autoantibodies in Physiology and the Treatment of Disease. Methods in Molecular Biology, 2019, 1904, 53-81.	0.9	19
25	Acute vision loss in multiple sclerosis: Optic neuritis or central serous chorioretinopathy?. Multiple Sclerosis and Related Disorders, 2019, 27, 147-150.	2.0	2
26	A comparison of human natural monoclonal antibodies and aptamer conjugates for promotion of CNS remyelination: where are we now and what comes next?. Expert Opinion on Biological Therapy, 2018, 18, 545-560.	3.1	13
27	Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 22, 103-107.	2.0	2
28	A natural human monoclonal antibody protects from axonal injury in different CNS degenerative disease models. Future Neurology, 2018, 13, 23-29.	0.5	1
29	Demyelination with preferential MAG loss: A complex message from MS paraffin blocks. Journal of the Neurological Sciences, 2018, 385, 126-130.	0.6	4
30	An Assay that Predicts InÂVivo Efficacy for DNA Aptamers that Stimulate Remyelination in a Mouse Model of Multiple Sclerosis. Molecular Therapy - Methods and Clinical Development, 2018, 9, 270-277.	4.1	2
31	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 739-749.	3.0	34
32	Dietary factors and pediatric multiple sclerosis: A case-control study. Multiple Sclerosis Journal, 2018, 24, 1067-1076.	3.0	27
33	Genetic risk factors for pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1825-1834.	3.0	37
34	Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 28-33.	1.9	74
35	Multiple Sclerosis. Neurologic Clinics, 2018, 36, 1-11.	1.8	103
36	Lipid Membranes: Curvature Elasticityâ€Driven Leaflet Asymmetry and Interleaflet Raft Coupling in Supported Membranes (Adv. Mater. Interfaces 23/2018). Advanced Materials Interfaces, 2018, 5, 1870117.	3.7	0

#	Article	IF	Citations
37	Heterogeneity in association of remote herpesvirus infections and pediatric <scp>MS</scp>. Annals of Clinical and Translational Neurology, 2018, 5, 1222-1228.	3.7	25
38	Curvature Elasticityâ€Driven Leaflet Asymmetry and Interleaflet Raft Coupling in Supported Membranes. Advanced Materials Interfaces, 2018, 5, 1801290.	3.7	4
39	Urban air quality and associations with pediatric multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1146-1153.	3.7	29
40	Several household chemical exposures are associated with pediatricâ€onset multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1513-1521.	3.7	8
41	Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology, 2018, 91, e1778-e1787.	1.1	55
42	Surface Plasmon Resonance Sensing on Naturally Derived Membranes: A Remyelination-Promoting Human Antibody Binds Myelin with Extraordinary Affinity. Analytical Chemistry, 2018, 90, 12567-12573.	6.5	5
43	Timing of Future Remyelination Therapies and Their Potential to Stop Multiple Sclerosis Progression. Advances in Experimental Medicine and Biology, 2017, 958, 161-170.	1.6	1
44	Sublethal oligodendrocyte injury: A reversible condition in multiple sclerosis?. Annals of Neurology, 2017, 81, 811-824.	5.3	30
45	Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology, 2017, 88, 1623-1629.	1.1	138
46	The Spectrum of Inflammatory Acquired Demyelinating Syndromes in Children. Seminars in Pediatric Neurology, 2017, 24, 189-200.	2.0	24
47	Examining the contributions of environmental quality to pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 18, 164-169.	2.0	21
48	Human Gut-Derived Commensal Bacteria Suppress CNS Inflammatory and Demyelinating Disease. Cell Reports, 2017, 20, 1269-1277.	6.4	218
49	Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis. Human Antibodies, 2017, 25, 121-129.	1.5	7
50	Biomarkers in radiologically isolated syndrome: The missing piece in the puzzle of treatment indication?. Journal of the Neurological Sciences, 2017, 375, 129.	0.6	1
51	Concomitant Use of Neuroprotective Drugs in Neuro Rehabilitation of Multiple Sclerosis. International Journal of Physical Medicine & Rehabilitation, 2016, 4, .	0.5	1
52	Characteristics of Children and Adolescents With Multiple Sclerosis. Pediatrics, 2016, 138, .	2.1	89
53	Dietary salt intake and time to relapse in paediatric multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1350-1353.	1.9	58
54	Distinct effects of obesity and puberty on risk and age at onset of pediatric MS. Annals of Clinical and Translational Neurology, 2016, 3, 897-907.	3.7	67

#	Article	IF	Citations
55	A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 6, 87-92.	2.0	58
56	A monoclonal natural human IgM protects axons in the absence of remyelination. Journal of Neuroinflammation, 2016, 13, 94.	7.2	10
57	Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Scientific Reports, 2016, 6, 28484.	3.3	660
58	Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study. Journal of Visualized Experiments, 2016, , .	0.3	1
59	Human class I major histocompatibility complex alleles determine central nervous system injury versus repair. Journal of Neuroinflammation, 2016, 13, 293.	7.2	3
60	AMP-Activated Protein Kinase Suppresses Autoimmune Central Nervous System Disease by Regulating M1-Type Macrophageâ€“Th17 Axis. Journal of Immunology, 2016, 197, 747-760.	0.8	25
61	Gut microbiota composition and relapse risk in pediatric MS: A pilot study. Journal of the Neurological Sciences, 2016, 363, 153-157.	0.6	137
62	Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. Expert Opinion on Biological Therapy, 2016, 16, 827-839.	3.1	21
63	Clinical features of neuromyelitis optica in children. Neurology, 2016, 86, 245-252.	1.1	100
64	Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease. Molecular Neurobiology, 2016, 53, 5217-5228.	4.0	22
65	The progeroid gene BubR1 regulates axon myelination and motor function. Aging, 2016, 8, 2667-2688.	3.1	23
66	Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression. Current Pharmaceutical Design, 2016, 22, 1049-1059.	1.9	15
67	Multiple Sclerosis, Gut Microbiota and Permeability: Role of Tryptophan Catabolites, Depression and the Driving Down of Local Melatonin. Current Pharmaceutical Design, 2016, 22, 6134-6141.	1.9	27
68	Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression. Current Pharmaceutical Design, 2016, 22, 1049-59.	1.9	7
69	Polysialic acid as an antigen for monoclonal antibody <scp>HI</scp>gM12 to treat multiple sclerosis and other neurodegenerative disorders. Journal of Neurochemistry, 2015, 134, 865-878.	3.9	15
70	Antiviral Protection via RdRP-Mediated Stable Activation of Innate Immunity. PLoS Pathogens, 2015, 11, e1005311.	4.7	23
71	A single dose of a neuron-binding human monoclonal antibody improves brainstem NAA concentrations, a biomarker for density of spinal cord axons, in a model of progressive multiple sclerosis. Journal of Neuroinflammation, 2015, 12, 83.	7.2	10
72	A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis. DMM Disease Models and Mechanisms, 2015, 8, 831-42.	2.4	38

#	Article	IF	Citations
73	Quantitative PCR Analysis of DNA Aptamer Pharmacokinetics in Mice. Nucleic Acid Therapeutics, 2015, 25, 11-19.	3.6	22
74	Human-derived natural antibodies: biomarkers and potential therapeutics. Future Neurology, 2015, 10, 25-39.	0.5	16
75	Ebola virus: Melatonin as a readily available treatment option. Journal of Medical Virology, 2015, 87, 537-543.	5.0	42
76	The US Network of Pediatric Multiple Sclerosis Centers. Journal of Child Neurology, 2015, 30, 1381-1387.	1.4	21
77	Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology, 2015, 85, 722-729.	1.1	86
78	Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases. JAMA Neurology, 2015, 72, 1346.	9.0	16
79	Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis. Journal of Biological Chemistry, 2015, 290, 30697-30712.	3.4	76
80	Multiple sclerosis: The role of melatonin and N-acetylserotonin. Multiple Sclerosis and Related Disorders, 2015, 4, 112-123.	2.0	33
81	Relapses and disability accumulation in progressive multiple sclerosis. Neurology, 2015, 84, 81-88.	1.1	92
82	Imaging of multiple sclerosis and related acquired demyelinating disorders in childhood. Journal of Pediatric Neuroradiology, 2015, 02, 057-072.	0.1	1
83	Abbreviated Exposure to Hypoxia Is Sufficient to Induce CNS Dysmyelination, Modulate Spinal Motor Neuron Composition, and Impair Motor Development in Neonatal Mice. PLoS ONE, 2015, 10, e0128007.	2.5	18
84	A human anti-polysialic acid antibody as a potential treatment to improve function in multiple sclerosis patients. Journal of Nature and Science, 2015, 1, .	1.1	1
85	Tryptophan Metabolites and Their Impact on Multiple Sclerosis Progression. Current Pharmaceutical Design, 2015, , .	1.9	0
86	Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response. Biological Chemistry, 2014, 395, 1063-1073.	2.5	20
87	Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases. Expert Review of Neurotherapeutics, 2014, 14, 449-463.	2.8	22
88	Protective environmental factors for neuromyelitis optica. Neurology, 2014, 83, 1923-1929.	1.1	23
89	Absence of IFN-Î³ Increases Brain Pathology in Experimental Autoimmune Encephalomyelitisâ€“Susceptible DRB1*0301.DQ8 HLA Transgenic Mice through Secretion of Proinflammatory Cytokine IL-17 and Induction of Pathogenic Monocytes/Microglia into the Central Nervous System. Journal of Immunology, 2014, 193, 4859-4870.	0.8	34
90	Formation of Biomembrane Microarrays with a Squeegee-based Assembly Method. Journal of Visualized Experiments, 2014, , .	0.3	1

#	Article	IF	Citations
91	Polyclonal and Monoclonal Antibodies in Clinic. Methods in Molecular Biology, 2014, 1060, 79-110.	0.9	30
92	Deletion of Virus-specific T-cells Enhances Remyelination in a Model of Multiple Sclerosis. , 2014, 2, .		5
93	Therapeutics to Promote CNS Repair: A Natural Human Neuron-Binding IgM Regulates Membrane-Raft Dynamics and Improves Motility in a Mouse Model of Multiple Sclerosis. Journal of Clinical Immunology, 2013, 33, 50-56.	3.8	8
94	Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire. Expert Review of Neurotherapeutics, 2013, 13, 1017-1029.	2.8	17
95	Novel Immunomodulatory Approaches for the Management of Multiple Sclerosis. Clinical Pharmacology and Therapeutics, 2013, 95, 32-44.	4.7	24
96	Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. BMC Neurology, 2013, 13, 173.	1.8	4
97	CD8⁺T cells in multiple sclerosis. Expert Opinion on Therapeutic Targets, 2013, 17, 1053-1066.	3.4	76
98	The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment. Expert Review of Clinical Immunology, 2013, 9, 535-549.	3.0	11
99	Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 891-895.	3.0	32
100	Cognitive Impairment Occurs in Children and Adolescents With Multiple Sclerosis. Journal of Child Neurology, 2013, 28, 102-107.	1.4	121
101	Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 188-198.	3.0	205
102	A patterned recombinant human IgM guides neurite outgrowth of CNS neurons. Scientific Reports, 2013, 3, 2267.	3.3	17
103	PDGF is Required for Remyelination-Promoting IgM Stimulation of Oligodendrocyte Progenitor Cell Proliferation. PLoS ONE, 2013, 8, e55149.	2.5	51
104	Nonequivalence of Classical MHC Class I Loci in Ability to Direct Effective Antiviral Immunity. PLoS Pathogens, 2012, 8, e1002541.	4.7	5
105	Statin therapy and multiple sclerosis disability in a population-based cohort. Multiple Sclerosis Journal, 2012, 18, 358-363.	3.0	11
106	Need for a paradigm shift in therapeutic approaches to CNS injury. Expert Review of Neurotherapeutics, 2012, 12, 409-420.	2.8	8
107	Is Multiple Sclerosis an Autoimmune Disease?. Autoimmune Diseases, 2012, 2012, 1-12.	0.6	63
108	Deletion of Betaâ€2â€Microglobulin Ameliorates Spinal Cord Lesion Load and Promotes Recovery of Brainstem NAA Levels in a Murine Model of Multiple Sclerosis. Brain Pathology, 2012, 22, 698-708.	4.1	13

#	Article	IF	Citations
109	Kallikrein 6 Regulates Early CNS Demyelination in a Viral Model of Multiple Sclerosis. Brain Pathology, 2012, 22, 709-722.	4.1	34
110	Preclinical ¹H-MRS neurochemical profiling in neurological and psychiatric disorders. Bioanalysis, 2012, 4, 1787-1804.	1.5	20
111	Two discreet subsets of CD8 T cells modulate PLP91â€“110 induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice. Journal of Autoimmunity, 2012, 38, 344-353.	6.5	45
112	High-Affinity Binding of Remyelinating Natural Autoantibodies to Myelin-Mimicking Lipid Bilayers Revealed by Nanohole Surface Plasmon Resonance. Analytical Chemistry, 2012, 84, 6031-6039.	6.5	38
113	Naturally Occurring Antibodies as Therapeutics for Neurologic Disease. Advances in Experimental Medicine and Biology, 2012, 750, 44-55.	1.6	6
114	Remyelination Induced by a DNA Aptamer in a Mouse Model of Multiple Sclerosis. PLoS ONE, 2012, 7, e39595.	2.5	41
115	Facile Assembly of Micro- and Nanoarrays for Sensing with Natural Cell Membranes. ACS Nano, 2011, 5, 7555-7564.	14.6	49
116	Pediatric Multiple Sclerosis. Neurologic Clinics, 2011, 29, 481-505.	1.8	53
117	Autoantibodies with enzymatic properties in human autoimmune diseases. Journal of Autoimmunity, 2011, 37, 144-150.	6.5	34
118	The relevance of animal models in multiple sclerosis research. Pathophysiology, 2011, 18, 21-29.	2.2	244
119	Disease-modifying therapy and response to first-line treatment in pediatric multiple sclerosis. , 2011, , 96-100.		1
120	Theiler's Murine Encephalomyelitis Virus as a Vaccine Candidate for Immunotherapy. PLoS ONE, 2011, 6, e20217.	2.5	25
121	A Single Dose of Neuron-Binding Human Monoclonal Antibody Improves Spontaneous Activity in a Murine Model of Demyelination. PLoS ONE, 2011, 6, e26001.	2.5	20
122	Evidence for the Role of B Cells and Immunoglobulins in the Pathogenesis of Multiple Sclerosis. Neurology Research International, 2011, 2011, 1-14.	1.3	25
123	A human IgM signals axon outgrowth: coupling lipid raft to microtubules. Journal of Neurochemistry, 2011, 119, 100-112.	3.9	26
124	Transgenic Expression of Viral Capsid Proteins Predisposes to Axonal Injury in aâ€ƒMurine Model of Multiple Sclerosis. Brain Pathology, 2011, 21, no-no.	4.1	11
125	Enhancing CNS Repair in Neurological Disease. CNS Drugs, 2011, 25, 555-573.	5.9	45
126	MRI in Rodent Models of Brain Disorders. Neurotherapeutics, 2011, 8, 3-18.	4.4	76

#	Article	IF	Citations
127	Beneficial Plasma Exchange Response in Central Nervous System Inflammatory Demyelination. Archives of Neurology, 2011, 68, 870.	4.5	173
128	Multiple Sclerosis Therapies in Pediatric Patients With Refractory Multiple Sclerosis. Archives of Neurology, 2011, 68, 437.	4.5	101
129	Antiviral Effects of a Transgenic RNA-Dependent RNA Polymerase. Journal of Virology, 2011, 85, 621-625.	3.4	17
130	Dalfampridine for the treatment of ambulatory impairment in multiple sclerosis. Future Neurology, 2010, 5, 637-643.	0.5	1
131	Method of Identifying Natural Antibodies for Remyelination. Journal of Clinical Immunology, 2010, 30, 50-55.	3.8	19
132	Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes. Glia, 2010, 58, 1782-1793.	4.9	52
133	CD8+ T Cells Cause Disability and Axon Loss in a Mouse Model of Multiple Sclerosis. PLoS ONE, 2010, 5, e12478.	2.5	34
134	Allelic variation in the Tyk2 and EGF genes as potential genetic determinants of CNS repair. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 792-797.	7.1	18
135	Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. Journal of Experimental Medicine, 2010, 207, 901-901.	8.5	0
136	Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination. Expert Review of Neurotherapeutics, 2010, 10, 441-457.	2.8	33
137	Novel Roles of the Picornaviral 3D Polymerase in Viral Pathogenesis. Advances in Virology, 2010, 2010, 1-9.	1.1	4
138	Treatment of multiple sclerosis in children and adolescents. Expert Opinion on Pharmacotherapy, 2010, 11, 505-520.	1.8	24
139	Invited Article: Human natural autoantibodies in the treatment of neurologic disease. Neurology, 2009, 72, 1269-1276.	1.1	43
140	Transgenic Expression of the 3D Polymerase Inhibits Theiler's Virus Infection and Demyelination. Journal of Virology, 2009, 83, 12279-12289.	3.4	15
141	Demyelinated Axons and Motor Function Are Protected by Genetic Deletion of Perforin in a Mouse Model of Multiple Sclerosis. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1037-1048.	1.7	43
142	Cellular Mechanisms of Central Nervous System Repair by Natural Autoreactive Monoclonal Antibodies. Archives of Neurology, 2009, 66, 1456-9.	4.5	47
143	HLA-DQ8 (DQB1*0302)-Restricted Th17 Cells Exacerbate Experimental Autoimmune Encephalomyelitis in HLA-DR3-Transgenic Mice. Journal of Immunology, 2009, 182, 5131-5139.	0.8	35
144	Brainstem ¹H nuclear magnetic resonance (NMR) spectroscopy: Marker of demyelination and repair in spinal cord. Annals of Neurology, 2009, 66, 559-564.	5.3	20

#	Article	IF	Citations
145	Have we finally identified an autoimmune demyelinating disease?. Annals of Neurology, 2009, 66, 572-573.	5.3	16
146	Tumor Necrosis Factor Î± is Reparative via TNFR1 in the Hippocampus and via TNFR2 in the Striatum after Virusâ€Induced Encephalitis. Brain Pathology, 2009, 19, 12-26.	4.1	24
147	Surface plasmon resonance for highâ€throughput ligand screening of membraneâ€bound proteins. Biotechnology Journal, 2009, 4, 1542-1558.	3.5	108
148	Plasmonic nanohole arrays for label-free kinetic biosensing in a lipid membrane environment. , 2009, 2009, 1481-4.		5
149	Seizures in Patients with Multiple Sclerosis. CNS Drugs, 2009, 23, 805-815.	5.9	93
150	Acute hemorrhagic demyelination in a murine model of multiple sclerosis. Journal of Neuroinflammation, 2008, 5, 31.	7.2	33
151	Human HLA-DR Transgenes Protect Mice from Fatal Virus-Induced Encephalomyelitis and Chronic Demyelination. Journal of Virology, 2008, 82, 3369-3380.	3.4	4
152	HLA-DQ6 (DQB1*0601)-Restricted T Cells Protect against Experimental Autoimmune Encephalomyelitis in HLA-DR3.DQ6 Double-Transgenic Mice by Generating Anti-Inflammatory IFN-Î³. Journal of Immunology, 2008, 180, 7747-7756.	0.8	24
153	Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biological Chemistry, 2008, 389, 739-745.	2.5	68
154	TREM-2 Mediated Signaling Induces Antigen Uptake and Retention in Mature Myeloid Dendritic Cells. Journal of Immunology, 2008, 181, 7863-7872.	0.8	13
155	A recombinant human IgM promotes myelin repair after a single, very low dose. Journal of Neuroscience Research, 2007, 85, 967-976.	2.9	124
156	Genetic Deletion of a Single Immunodominant T-cell Response Confers Susceptibility to Virus-induced Demyelination. Brain Pathology, 2007, 17, 184-196.	4.1	14
157	Effectors of Demyelination and Remyelination in the CNS: Implications for Multiple Sclerosis. Brain Pathology, 2007, 17, 219-229.	4.1	75
158	Absence of perforin expression confers axonal protection despite demyelination. Neurobiology of Disease, 2007, 25, 354-359.	4.4	56
159	CD8+ T cells directed against a viral peptide contribute to loss of motor function by disrupting axonal transport in a viral model of fulminant demyelination. Journal of Neuroimmunology, 2007, 188, 13-21.	2.3	41
160	A New Humanized HLA Transgenic Mouse Model of Multiple Sclerosis Expressing Class II on Mouse CD4 T Cells. Annals of the New York Academy of Sciences, 2007, 1103, 112-117.	3.8	9
161	MRI findings in benign multiple sclerosis are variable. Journal of Neurology, 2007, 254, 539-541.	3.6	9
162	Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: The Mayo Clinic experience. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1178-1186.	0.8	39

#	Article	IF	Citations
163	Activated microglia stimulate transcriptional changes in primary oligodendrocytes via IL-1Î². Neurobiology of Disease, 2006, 23, 731-739.	4.4	24
164	Disrupted spatial memory is a consequence of picornavirus infection. Neurobiology of Disease, 2006, 24, 266-273.	4.4	50
165	Role of MHC class II expressing CD4+ T cells in proteolipid protein91â€“110-induced EAE in HLA-DR3 transgenic mice. European Journal of Immunology, 2006, 36, 3356-3370.	2.9	20
166	Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis. Archives of Neurology, 2006, 63, 611.	4.5	54
167	Premenstrual Multiple Sclerosis Pseudoexacerbations. Archives of Neurology, 2006, 63, 1005.	4.5	27
168	Later-Onset Fabry Disease. Archives of Neurology, 2006, 63, 453.	4.5	52
169	STAT4â€•and STAT6â€‘signaling molecules in a murine model of multiple sclerosis. FASEB Journal, 2006, 20, 343-345.	0.5	13
170	Induction of a gene expression program in dendritic cells with a cross-linking IgM antibody to the co-stimulatory molecule B7-DC. FASEB Journal, 2006, 20, 2408-2410.	0.5	15
171	Delineation of the minimal encephalitogenic epitope of proteolipid protein peptide91â€“110 and critical residues required for induction of EAE in HLA-DR3 transgenic mice. Journal of Neuroimmunology, 2005, 161, 40-48.	2.3	4
172	HLA DR and DQ interaction in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in HLA class II transgenic mice. Journal of Neuroimmunology, 2005, 169, 1-12.	2.3	34
173	Remyelination as Neuroprotection. , 2005, , 389-419.		3
174	Neutralization of chemokines RANTES and MIG increases virus antigen expression and spinal cord pathology during Theiler's virus infection. International Immunology, 2005, 17, 569-579.	4.0	20
175	Antigen-Specific CD8+ T Cells Mediate a Peptide-Induced Fatal Syndrome. Journal of Immunology, 2005, 174, 6854-6862.	0.8	36
176	Inability of bm14 Mice to Respond to Theilerâ€™s Murine Encephalomyelitis Virus Is Caused by Defective Antigen Presentation, Not Repertoire Selection. Journal of Immunology, 2005, 174, 2756-2762.	0.8	4
177	Anatomical and Cellular Requirements for the Activation and Migration of Virus-Specific CD8+ T Cells to the Brain during Theiler's Virus Infection. Journal of Virology, 2005, 79, 3063-3070.	3.4	24
178	Genetically Dominant Spinal Cord Repair in a Murine Model of Chronic Progressive Multiple Sclerosis. Journal of Neuropathology and Experimental Neurology, 2005, 64, 46-57.	1.7	27
179	Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet, The, 2005, 366, 579-582.	13.7	411
180	Magnetic resonance imaging, microscopy, and spectroscopy of the central nervous system in experimental animals. NeuroRx, 2005, 2, 250-264.	6.0	62

#	Article	IF	Citations
181	Magnetic resonance imaging, microscopy, and spectroscopy of the central nervous system in experimental animals. Neurotherapeutics, 2005, 2, 250-264.	4.4	0
182	Disappearing "T1 black holes" in an animal model of multiple sclerosis. Frontiers in Bioscience - Landmark, 2004, 9, 1222.	3.0	19
183	Quality of Life Is Favorable for Most Patients With Multiple Sclerosis. Archives of Neurology, 2004, 61, 679.	4.5	116
184	Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Multiple Sclerosis Journal, 2004, 10, 85-86.	3.0	28
185	In vivo magnetic resonance imaging of immune cells in the central nervous system with superparamagnetic antibodies. FASEB Journal, 2004, 18, 179-182.	0.5	78
186	Pulsed Intravenous Methylprednisolone Therapy in Progressive Multiple Sclerosis: Need for a Controlled Trial. Archives of Neurology, 2004, 61, 1148-9.	4.5	12
187	A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2â€weighted spinal cord MRI in a virusâ€induced murine model of MS. FASEB Journal, 2004, 18, 1577-1579.	0.5	100
188	Immunotherapeutic Potential of B7-DC (PD-L2) Cross-Linking Antibody In Conferring Antitumor Immunity. Cancer Research, 2004, 64, 4965-4972.	0.9	61
189	Targeting kallikrein 6â€proteolysis attenuates CNS inflammatory disease. FASEB Journal, 2004, 18, 920-922.	0.5	91
190	CD4+ T cells are important for clearance of DA strain of TMEV from the central nervous system of SJL/J mice. International Immunology, 2004, 16, 1237-1240.	4.0	8
191	The role of cellular immune response in Theiler's virus-induced central nervous system demyelination. Journal of Neuroimmunology, 2004, 147, 73-77.	2.3	11
192	Antibody-mediated remyelination operates through mechanism independent of immunomodulation. Journal of Neuroimmunology, 2004, 146, 153-161.	2.3	37
193	Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. Annals of Neurology, 2004, 56, 303-306.	5.3	197
194	Identification of T cell epitopes on human proteolipid protein and induction of experimental autoimmune encephalomyelitis in HLA classâ€„II-transgenic mice. European Journal of Immunology, 2004, 34, 280-290.	2.9	39
195	Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. Movement Disorders, 2004, 19, 1482-1485.	3.9	96
196	Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiology of Disease, 2004, 15, 120-131.	4.4	60
197	Dynamics of MRI lesion development in an animal model of viral-induced acute progressive CNS demyelination. NeuroImage, 2004, 21, 576-582.	4.2	36
198	Neuron-Binding Human Monoclonal Antibodies Support Central Nervous System Neurite Extension. Journal of Neuropathology and Experimental Neurology, 2004, 63, 461-473.	1.7	46

#	Article	IF	Citations
199	Clearance of Theiler's virus infection depends on the ability to generate a CD8⁺ Tâ€„cell response against a single immunodominant viral peptide. European Journal of Immunology, 2003, 33, 2501-2510.	2.9	61
200	Efficient central nervous system remyelination requires T cells. Annals of Neurology, 2003, 53, 680-684.	5.3	169
201	More severe neurologic deficits in SJL/J male than female mice following Theilerâ€™s virus-induced CNS demyelination. Experimental Neurology, 2003, 180, 14-24.	4.1	36
202	Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Molecular and Cellular Neurosciences, 2003, 22, 14-24.	2.2	79
203	A function of myelin is to protect axons from subsequent injury: implications for deficits in multiple sclerosis. Brain, 2003, 126, 751-752.	7.6	58
204	Naturally Occurring Human IgM Antibody That Binds B7-DC and Potentiates T Cell Stimulation by Dendritic Cells. Journal of Immunology, 2003, 170, 1830-1838.	0.8	65
205	Gamma Interferon Is Critical for Neuronal Viral Clearance and Protection in a Susceptible Mouse Strain following Early Intracranial Theiler's Murine Encephalomyelitis Virus Infection. Journal of Virology, 2003, 77, 12252-12265.	3.4	80
206	Membrane lymphotoxin is required for resistance to Theiler's virus infection. International Immunology, 2003, 15, 955-962.	4.0	20
207	HLA class II transgenic mice authenticate restriction of myelin oligodendrocyte glycoprotein-specific immune response implicated in multiple sclerosis pathogenesis. International Immunology, 2003, 15, 535-546.	4.0	26
208	Chapter 13 Treatment of Catastrophic Multiple Sclerosis. Blue Books of Practical Neurology, 2003, 27, 207-216.	0.1	0
209	Interleukin-6 Protects Anterior Horn Neurons from Lethal Virus-Induced Injury. Journal of Neuroscience, 2003, 23, 481-492.	3.6	67
210	Direct Comparison of Demyelinating Disease Induced by the Daniel's Strain and BeAn Strain of Theiler's Murine Encephalomyelitis Virus. Brain Pathology, 2003, 13, 291-308.	4.1	39
211	A 40â€cM Region on Chromosome 14 Plays a Critical Role in the Development of Virus Persistence, Demyelination, Brain Pathology and Neurologic Deficits in a Murine Viral Model of Multiple Sclerosis. Brain Pathology, 2003, 13, 519-533.	4.1	6
212	Human Monoclonal IgM Antibody Promotes CNS Myelin Repair Independent of Fc Function. Brain Pathology, 2003, 13, 608-616.	4.1	28
213	Magnetic resonance imaging of immune cells in inflammation of central nervous system. Croatian Medical Journal, 2003, 44, 463-8.	0.7	17
214	Cross-linking the B7 Family Molecule B7-DC Directly Activates Immune Functions of Dendritic Cells. Journal of Experimental Medicine, 2002, 196, 1393-1398.	8.5	96
215	Transgenic Expression of Theiler's Murine Encephalomyelitis Virus Genes in H-2b Mice Inhibits Resistance to Virus-Induced Demyelination. Journal of Virology, 2002, 76, 7799-7811.	3.4	21
216	Heterogeneity of Pathogenesis in Multiple Sclerosis: Implications for Promotion of Remyelination. Journal of Infectious Diseases, 2002, 186, S248-S253.	4.0	13

#	Article	IF	Citations
217	Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB Journal, 2002, 16, 1260-1262.	0.5	71
218	Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronicâ€progressive demyelinating disease. FASEB Journal, 2002, 16, 1325-1327.	0.5	81
219	Incidence of Seizures in Patients With Multiple Sclerosis: A Population-Based Study. Mayo Clinic Proceedings, 2002, 77, 910-912.	3.0	19
220	Enzymatic Properties of Rat Myelencephalon-Specific Protease. Biochemistry, 2002, 41, 1165-1173.	2.5	79
221	Growth factor treatment of demyelinating disease: at last, a leap into the light. Trends in Immunology, 2002, 23, 512-516.	6.8	40
222	Incidence of Seizures in Patients With Multiple Sclerosis: A Population-Based Study. Mayo Clinic Proceedings, 2002, 77, 910-912.	3.0	23
223	Cellular sources and targets of IFN-Î³-mediated protection against viral demyelination and neurological deficits. European Journal of Immunology, 2002, 32, 606.	2.9	30
224	Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia, 2002, 37, 241-249.	4.9	98
225	Internalization and Sorting of Plasma Membrane Sphingolipid Analogues in Differentiating Oligodendrocytes. Journal of Neurochemistry, 2002, 73, 1375-1383.	3.9	29
226	ICAM-1 is crucial for protection from TMEV-induced neuronal damage but not demyelination. Journal of NeuroVirology, 2002, 8, 452-458.	2.1	9
227	Immunoglobulin-mediated CNS repairâ˜†â˜†â˜†.... Journal of Allergy and Clinical Immunology, 2001, 108, S121-S125.	2.5	28
228	Humoral autoimmunity as a mediator of CNS repair. Trends in Neurosciences, 2001, 24, S39-S44.	8.6	49
229	Humoral autoimmunity as a mediator of CNS repair. Trends in Neurosciences, 2001, 24, 39-44.	8.6	525
230	Seizures in Patients With Multiple Sclerosis Seen at Mayo Clinic, Rochester, Minn, 1990â€“1998. Mayo Clinic Proceedings, 2001, 76, 983-986.	3.0	46
231	Clonal evolution in Waldenstrom macroglobulinemia highlights functional role of B-cell receptor. Blood, 2001, 97, 321-323.	1.4	43
232	MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. Journal of Comparative Neurology, 2001, 431, 347-361.	1.6	65
233	Antigens to viral capsid and non-capsid proteins are present in brain tissues and antibodies in sera of Theiler's virus-infected mice. Journal of Virological Methods, 2001, 91, 11-19.	2.1	8
234	Preservation of motor function by inhibition of CD8+ virus peptideâ€specific T cells in Theiler's virus infection. FASEB Journal, 2001, 15, 1-22.	0.5	65

#	Article	IF	Citations
235	Extensive Injury of Descending Neurons Demonstrated by Retrograde Labeling in a Virus-Induced Murine Model of Chronic Inflammatory Demyelination. Journal of Neuropathology and Experimental Neurology, 2000, 59, 664-678.	1.7	21
236	Short-term treatment with interferon-?/? promotes remyelination, whereas long-term treatment aggravates demyelination in a murine model of multiple sclerosis. , 2000, 59, 661-670.		28
237	Preferential expression of myelencephalon-specific protease by oligodendrocytes of the adult rat spinal cord white matter. , 2000, 30, 219-230.		34
238	Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Annals of Neurology, 2000, 47, 707-717.	5.3	2,892
239	Neurotrophin-4/5 promotes proliferation of oligodendrocyte-type-2 astrocytes (O-2A). Developmental Brain Research, 2000, 123, 87-90.	1.7	15
240	Assessment of hindlimb gait as a powerful indicator of axonal loss in a murine model of progressive CNS demyelination. Brain Research, 2000, 877, 396-400.	2.2	19
241	The CD4-Mediated Immune Response Is Critical in Determining the Outcome of Infection Using Theiler's Viruses with VP1 Capsid Protein Point Mutations. Virology, 2000, 275, 9-19.	2.4	10
242	TGF-Î²2 Reduces Demyelination, Virus Antigen Expression, and Macrophage Recruitment in a Viral Model of Multiple Sclerosis. Journal of Immunology, 2000, 164, 3207-3213.	0.8	37
243	VÎ²8+ T cells protect from demyelinating disease in a viral model of multiple sclerosis. International Immunology, 2000, 12, 271-280.	4.0	8
244	HLA-DQ Polymorphism Influences Progression of Demyelination and Neurologic Deficits in a Viral Model of Multiple Sclerosis. Molecular and Cellular Neurosciences, 2000, 15, 495-509.	2.2	10
245	Quantitative Ultrastructural Analysis of a Single Spinal Cord Demyelinated Lesion Predicts Total Lesion Load, Axonal Loss, and Neurological Dysfunction in a Murine Model of Multiple Sclerosis. American Journal of Pathology, 2000, 157, 1365-1376.	3.8	59
246	Complementation between specific HLA-DR and HLA-DQ genes in transgenic mice determines susceptibility to experimental autoimmune encephalomyelitis. Human Immunology, 2000, 61, 279-289.	2.4	47
247	Concurrence of Inflammatory Bowel Disease and Multiple Sclerosis. Mayo Clinic Proceedings, 2000, 75, 802-806.	3.0	99
248	Multiple Sclerosis. New England Journal of Medicine, 2000, 343, 938-952.	27.0	3,121
249	CD40L is Critical for Protection from Demyelinating Disease and Development of Spontaneous Remyelination in a Mouse Model of Multiple Sclerosis. Brain Pathology, 2000, 10, 1-15.	4.1	15
250	Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. , 2000, 47, 707.		16
251	Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. , 2000, 47, 707.		1
252	A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. Brain, 1999, 122, 2279-2295.	7.6	436

#	Article	IF	Citations
253	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Annals of Neurology, 1999, 46, 878-886.	5.3	832
254	Quantitation of spinal cord demyelination, remyelination, atrophy, and axonal loss in a model of progressive neurologic injury. Journal of Neuroscience Research, 1999, 58, 492-504.	2.9	100
255	Quantitative Assessment of Neurologic Deficits in a Chronic Progressive Murine Model of CNS Demyelination. Experimental Neurology, 1999, 158, 171-181.	4.1	66
256	Absence of Spontaneous Central Nervous System Remyelination in Class ll-deficient Mice Infected with TheilerÊ¼s Virus. Journal of Neuropathology and Experimental Neurology, 1999, 58, 78-91.	1.7	30
257	CNS Cell Populations are Protected from Virusâ€Induced Pathology by Distinct Arms of the Immune System. Brain Pathology, 1999, 9, 21-31.	4.1	25
258	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. , 1999, 46, 878.		2
259	Differential Influence of Interleukin-12 in the Pathogenesis of Autoimmune and Virus-Induced Central Nervous System Demyelination. Journal of Virology, 1999, 73, 1637-1639.	3.4	36
260	Prevalent Class I-Restricted T-Cell Response to the Theilerâ€™s Virus Epitope D^b:VP2_{121â€“130}in the Absence of Endogenous CD4 Help, Tumor Necrosis Factor Alpha, Gamma Interferon, Perforin, or Costimulation through CD28. Journal of Virology, 1999, 73, 3702-3708.	3.4	109
261	Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nature Medicine, 1998, 4, 187-193.	30.7	208
262	Failure of treatment with Linomide or oral myelin tolerization to ameliorate demyelination in a viral model of multiple sclerosis. Journal of Neuroimmunology, 1998, 88, 111-119.	2.3	12
263	Differentiation-specific mRNA expression of a mouse bipotential glial cell line. Neuroscience Letters, 1998, 258, 21-24.	2.1	2
264	Acute Disseminated Encephalomyelitis After Accidental Injection of a Hog Vaccine: Successful Treatment With Plasmapheresis. Mayo Clinic Proceedings, 1998, 73, 1193-1195.	3.0	26
265	Interferon-Î³ in Progression to Chronic Demyelination and Neurological Deficit Following Acute EAE. Molecular and Cellular Neurosciences, 1998, 12, 376-389.	2.2	94
266	Retinocochleocerebral Vasculopathy. Medicine (United States), 1998, 77, 12-40.	1.0	118
267	Perforin-Dependent Neurologic Injury in a Viral Model of Multiple Sclerosis. Journal of Neuroscience, 1998, 18, 7306-7314.	3.6	107
268	Targeting of IgMÎº Antibodies to Oligodendrocytes Promotes CNS Remyelination. Journal of Neuroscience, 1998, 18, 7700-7708.	3.6	99
269	Acceleration in the Rate of CNS Remyelination in Lysolecithin-Induced Demyelination. Journal of Neuroscience, 1998, 18, 2498-2505.	3.6	127
270	Molecular Characterization of a Nondemyelinating Variant of Danielâ€™s Strain of Theilerâ€™s Virus Isolated from a Persistently Infected Glioma Cell Line. Journal of Virology, 1998, 72, 1262-1269.	3.4	18

#	Article	IF	Citations
271	The Controversy Surrounding the Pathogenesis of the Multiple Sclerosis Lesion. Mayo Clinic Proceedings, 1997, 72, 665-678.	3.0	32
272	Remyelination in multiple sclerosis. Multiple Sclerosis Journal, 1997, 3, 133-136.	3.0	180
273	Enhancement of central nervous system remyelination in immune and non-immune experimental models of demyelination. Multiple Sclerosis Journal, 1997, 3, 76-79.	3.0	12
274	Monoclonal remyelination-promoting natural autoantibody SCH 94.03: pharmacokinetics and in vivo targets within demyelinated spinal cord in a mouse model of multiple sclerosis. Journal of the Neurological Sciences, 1997, 150, 103-113.	0.6	32
275	The Controversy Surrounding the Pathogenesis of the Multiple Sclerosis Lesion. Mayo Clinic Proceedings, 1997, 72, 665-678.	3.0	39
276	Successful treatment of established relapsing experimental autoimmune encephalomyelitis in mice with a monoclonal natural autoantibody. Journal of Neuroimmunology, 1997, 75, 204-209.	2.3	42
277	Antiviral immune responses modulate the nature of central nervous system (CNS) disease in a murine model of multiple sclerosis. Immunological Reviews, 1997, 159, 177-193.	6.0	57
278	Primary demyelination in transgenic mice expressing interferon-Î³. Nature Medicine, 1997, 3, 1037-1041.	30.7	167
279	Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factorâ€Î± in the central nervous system. European Journal of Immunology, 1997, 27, 905-913.	2.9	137
280	Differential generation of class I H-2D- versus H-2K-restricted cytotoxicity against a demyelinating virus following central nervous system infection. European Journal of Immunology, 1997, 27, 963-970.	2.9	38
281	Effects of Transforming Growth Factorâ€Î² and Plateletâ€Derived Growth Factor on Oligodendrocyte Precursors: Insights Gained from a Neuronal Cell Line. Journal of Neurochemistry, 1997, 68, 2281-2290.	3.9	40
282	Strategies to Promote Central Nervous System Remyelination In Vivo. , 1997, , 297-311.		0
283	The Repair of Central Nervous System Myelin. , 1997, , 253-264.		1
284	Multiple sclerosis: a unique immunopathological syndrome of the central nervous system. , 1996, , 89-105.		0
285	A monoclonal autoantibody which promotes central nervous system remyelination is highly polyreactive to multiple known and novel antigens. Journal of Neuroimmunology, 1996, 65, 11-19.	2.3	39
286	Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis. Brain Pathology, 1996, 6, 259-274.	4.1	712
287	Central Nervous System Remyelination Clinical Application of Basic Neuroscience Principles. Brain Pathology, 1996, 6, 331-344.	4.1	34
288	Subacute encephalomyelitis presenting as stiff-person syndrome: Clinical, polygraphic, and pathologic correlations. Movement Disorders, 1996, 11, 701-709.	3.9	30

#	Article	IF	Citations
289	A monoclonal natural autoantibody that promotes remyelination suppresses central nervous system inflammation and increases virus expression after Theiler's virus-induced demyelination. International Immunology, 1996, 8, 131-141.	4.0	32
290	H-2 Ddtransgene suppresses Theiler's virus-induced demyelination in susceptible strains of mice. Journal of NeuroVirology, 1995, 1, 111-117.	2.1	48
291	Spontaneous and induced remyelination in multiple sclerosis and the theiler's virus model of central nervous system demyelination. Microscopy Research and Technique, 1995, 32, 230-245.	2.2	25
292	Multiple sclerosis: a unique immunopathological syndrome of the central nervous system. Seminars in Immunopathology, 1995, 17, 89-105.	4.0	19
293	VP1 and VP2 Capsid Proteins of Theiler's Virus Are Targets of H-2D-Restricted Cytotoxic Lymphocytes in the Central Nervous System of B10 Mice. Virology, 1995, 214, 91-99.	2.4	46
294	Oligodendrocyte-reactive O1, O4, and HNK-1 monoclonal antibodies are encoded by germline immunoglobulin genes. Molecular Brain Research, 1995, 34, 283-293.	2.3	23
295	Ultrastructure of Multiple Sclerosis. Ultrastructural Pathology, 1994, 18, 3-13.	0.9	144
296	Influence of Deletion of T Cell Receptor VÎ²Genes on the Theiler's Virus Model of Multiple Sclerosis. Autoimmunity, 1994, 19, 221-230.	2.6	12
297	Polyclonal Ig: an immunopharmacon?. Trends in Immunology, 1994, 15, 341-342.	7.5	0
298	Motor and somatosensory evoked potentials in mice infected with Theiler's murine encephalomyelitis virus. Journal of the Neurological Sciences, 1994, 123, 186-194.	0.6	17
299	Chapter 28 Immune promotion of central nervous system remyelination. Progress in Brain Research, 1994, 103, 343-355.	1.4	17
300	Proteolipid Protein Gene Expression in Demyelination and Remyelination of the Central Nervous System: A Model for Multiple Sclerosis. Journal of Neuropathology and Experimental Neurology, 1994, 53, 136-143.	1.7	41
301	Oligodendrocyte Injury Is an Early Event in Lesions of Multiple Sclerosis. Mayo Clinic Proceedings, 1993, 68, 627-636.	3.0	124
302	The Potential for Oligodendrocyte Proliferation During Demyelinating Disease. Journal of Neuropathology and Experimental Neurology, 1993, 52, 55-63.	1.7	83
303	Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology, 1993, 43, 1100-1100.	1.1	109
304	Immunosuppression promotes CNS remyelination in chronic virusâ€induced demyelinating disease. Neurology, 1992, 42, 348-348.	1.1	84
305	Coexpression of Class I Major Histocompatibility Antigen and Viral RNA in Central Nervous System of Mice Infected With Theiler's Virus: A Model for Multiple Sclerosis. Mayo Clinic Proceedings, 1992, 67, 829-838.	3.0	23
306	Central nervous system demyelination and remyelination in multiple sclerosis and viral models of disease. Journal of Neuroimmunology, 1992, 40, 255-263.	2.3	38

#	Article	IF	Citations
307	Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Annals of Neurology, 1992, 31, 262-267.	5.3	151
308	Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Annals of Neurology, 1992, 32, 834-835.	5.3	98
309	Role of T cells in resistance to Theiler's virus infection. Microbial Pathogenesis, 1991, 11, 269-281.	2.9	33
310	Human T-Cell Lymphotropic Virus Type I Sequences Detected by Nested Polymerase Chain Reactions Are Not Associated With Multiple Sclerosis. Mayo Clinic Proceedings, 1991, 66, 665-680.	3.0	11
311	Persistence of TheilerÊ¼s Virus Infection Following Promotion of Central Nervous System Remyelination. Journal of Neuropathology and Experimental Neurology, 1991, 50, 523-537.	1.7	11
312	The treatable dementia of sjÃ¶gren's syndrome. Annals of Neurology, 1991, 30, 98-101.	5.3	68
313	Immunoglobulins promote remyelination in the central nervous system. Annals of Neurology, 1990, 27, 12-17.	5.3	223
314	Inhibition of Theiler's Virus-induced demylination in vivo by tumor necrosis factor alpha. International Immunology, 1990, 2, 909-913.	4.0	54
315	Theiler's virus-induced demyelination in mice immunosuppressed with anti-IgM and in mice expressing the xid gene. Microbial Pathogenesis, 1990, 8, 23-35.	2.9	41
316	Multiple Sclerosis: Basic Concepts and Hypothesis. Mayo Clinic Proceedings, 1989, 64, 570-576.	3.0	52
317	Anti-Î¼ treatment suppresses immunoglobulin light-chain gene expression and Peyer's patch development. Molecular Immunology, 1989, 26, 351-358.	2.2	3
318	Erichrome Stain for Myelin on Osmicated Tissue Embedded in Glycol Methacrylate Plastic. Journal of Histotechnology, 1989, 12, 35-36.	0.5	38
319	Erichrome Stain for Myelin on Osmicated Tissue Embedded in Glycol Methacrylate Plastic. Journal of Histotechnology, 1989, 12, 35-36.	0.5	2
320	Theiler's virus-associated antigens on the surfaces of cultured glial cells. Virology, 1988, 166, 463-474.	2.4	17
321	Mechanisms of Virus-Induced Demyelination and Remyelination. Annals of the New York Academy of Sciences, 1988, 540, 240-251.	3.8	6
322	Enumeration and Distribution of T-Cell Subsets, Macrophages, and IgG Positive Cells in the CNS of SJL/J Mice Infected with Theiler's Virus. Annals of the New York Academy of Sciences, 1988, 540, 657-660.	3.8	4
323	Remyelination by Oligodendrocytes Stimulated by Antiserum to Spinal Cord. Journal of Neuropathology and Experimental Neurology, 1987, 46, 84-95.	1.7	104
324	The Contribution of MHC Gene Products to Demyelination by Theilerâ€™s Virus. , 1987, , 747-756.		3

#	Article	IF	Citations
325	Effect of cyclosporin A, silica quartz dust, and protease inhibitors on virus-induced demyelination. Journal of Neuroimmunology, 1986, 13, 159-174.	2.3	51
326	Dysglobulinemic neuropathy: Absence of immunoglobulin within myelin sheaths. Annals of Neurology, 1986, 19, 204-206.	5.3	4
327	Immune-mediated injury of virus-infected oligodendrocytes A model of multiple sclerosis. Trends in Immunology, 1986, 7, 359-363.	7.5	50
328	Virus-Induced Demyelination in Mice: â€œDying Backâ€•of Oligodendrocytes. Mayo Clinic Proceedings, 1985, 60, 433-438.	3.0	70
329	Viral perturbation of endocrine function: disordered cell function leads to disturbed homeostasis and disease. Nature, 1984, 307, 278-281.	27.8	132
330	Microangiopathy of vasa nervorum in dysglobulinemic neuropathy. Annals of Neurology, 1984, 15, 386-394.	5.3	53
331	Persistent infection of oligodendrocytes in Theiler's virus-induced encephalomyelitis. Annals of Neurology, 1983, 13, 426-433.	5.3	258
332	Myasthenia gravis in children: Long-term follow-up. Annals of Neurology, 1983, 13, 504-510.	5.3	164
333	Central neurogenic hyperventilation in an awake patient with brainstem astrocytoma. Annals of Neurology, 1982, 11, 625-628.	5.3	40
334	Quantitation of spinal cord demyelination, remyelination, atrophy, and axonal loss in a model of progressive neurologic injury. , 0, .		1